Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia

Clinical Infectious Diseases

Volumn 35, Issue 7, 2002, Pages 825-833

  Ling, Judith ^a,e,f   Baird, J Kevin ^a   Fryauff, David J ^c   Sismadi, Priyanto ^b   Bangs, Michael J ^a   Lacy, Mark ^a   Barcus, Mazie J ^a   Gramzinski, Robert ^a   Maguire, Jason D ^a   Kumusumangsih, Marti ^c   Miller, Gerri B ^d   Jones, Trevor R ^c   Chulay, Jeffrey D ^d   Hoffman, Stephen L ^c,g  

^a US Naval Medical Research Unit No 2 Jakarta   (Indonesia)

^b MINISTRY OF HEALTH   (Indonesia)

^c Naval Medical Research Center   (Indonesia)

^d Children�s National Medical Center and George Washington University ^*  (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f KAISER PERMANENTE   (United States)

^g AlphaVax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE PLUS PROGUANIL; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENDEMIC DISEASE; FEMALE; HUMAN; INDONESIA; MAJOR CLINICAL STUDY; MALARIA; MALE; MIGRATION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; STOMATITIS;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHEMOPREVENTION; CHILD; CHLOROGUANIDE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDONESIA; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE; MIDDLE AGED; NAPHTHOQUINONES; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; TRANSIENTS AND MIGRANTS; TREATMENT OUTCOME;

EID: 0036788401     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342578     Document Type: Article

References (44)

1. White NJ. Antimalarial drug resistance: The pace quickens. J Antimicrob Chemother 1992; 30:571-85.
2. Baird JK, Basri H, Jones TR, Purnomo, Bangs MJ, Ritonga A. Resistance to antimalarials by Plasmodium falciparum in Arso PIR, Irian Jaya, Indonesia. Am J Trop Med Hyg 1991; 44:640-4.
3. Baird JK, Wiady I, Fryauff DJ, et al. In vivo resistance to chloroquine by P. Vivax and P. falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg 1997; 56:627-31.
4. Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK, Rieckmann KH. Chloroquine-resistant P. Vivax in Papua, New Guinea. Trans R Soc Trop Med Hyg 1992; 86:121-2.
5. Baird JK, Basri H, Purnomo, et al. Resistance to chloroquine by P. Vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 1991; 44:547-52.
6. Murphy GS, Basri H, Purnomo, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 1993; 341:96-100.
7. Nosten F, van Vugt M. Neuropsychiatric adverse effects of mefloquine: what do we know and what should we do? CNS Drugs 1999; 11:1-8.
8. Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35:451-8.
9. Bryant SG, Fisher S, Kluge RM. Increased frequency of doxycycline side effects. Pharmacotherapy 1987; 7:125-9.
10. Atovaquone/proguanil (Malarone) for malaria. Med Lett Drugs Ther 2000; 42:109-11.
11. Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1, 4-naphthoquinone (566C80). Biochem Pharmacol 1992; 43:1545-53.
12. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995; 80:373-81.
13. Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999; 43:1334-9.
14. Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone-proguanil for suppressive prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 1998; 27:494-9.
15. Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709-13.
16. Sukwa TY, Mulenga M, Chisaka N, Roskell NS, Scott TR. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone-proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999; 60:521-5.
17. Shanks GD, Kremsner PG, Sukwa TY, et al. Atovaquone and proguanil hydrochloride for prophylaxis of malaria. J Travel Med 1999; 6(Suppl 1):S21-7.
18. Takken W, Knols BJG. A taxonomic and bionomic review of the malaria vectors of Indonesia. Wageningen Agricultural University Papers 1990; 90:9-62.
19. Fryauff DJ, Baird JK, Basri H, et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995; 346:1190-3.
20. Blackwelder WC. Sample size and power for prospective analysis of relative risk. Stat Med 1993; 12:691-8.
21. Baird JK, Lacy MD, Basri H, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 2001; 33:1990-7.
22. DeAngelis DV, Long JD, Kanics LL, Woolley JL. High-performance liquid chromatographic assay for the measurement of atovaquone in plasma. J Chromatogr 1994; 652:211-9.
23. Hussein Z, Eaves CJ, Hutchinson DB, Canfield CJ. Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Br J Clin Pharmacol 1996; 42:589-97.
24. Lacy MD, Maguire JD, Barcus MJ, et al. Malarone (atovaquone/proguanil) therapy for Plasmodium falciparum and Plasmodium vivax in nonimmune Indonesians. Clin Infect Dis (in press).
25. Beerahee M. Clinical pharmacology of atovaquone and proguanil hydrochloride. J Travel Med 1999; 6(Suppl 1):S13-7.
26. Høgh B, Clarke PD, Camus D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Lancet 2000; 356:1888-94.
27. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travellers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33:1015-21.
28. El-Sadr WM, Murphy RL, Yurik TM, et al. A randomized trial of atovaquone versus dapsone for the prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection who are intolerant to trimethoprim and/or sulfonamides. N Engl J Med 1998; 339:1889-95.
29. Erikkson B, Bjorkman A, Keiau M. How safe is proguanil? A post-marketing investigation of side effects. Scand J Infect Dis 1991; 23:489-93.
30. Drysdale SF, Phillips-Howard PA, Behrens RH. Proguanil, chloroquine, and mouth ulcers. Lancet 1990; 335:164.
31. Andersen SL, Oloo AJ, Gordon DM, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 1998; 26:146-50.
32. Taylor WR, Richie TL, Fryauff DJ, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 1999; 28:74-81.
33. Van Thiel PH, Winoto RMP. Control of hyperendemic malaria on Java caused by Anopheles sundaicus by DDT house spraying. Trop Geogr Med 1951; 7:164-81.
34. Atmosoedjono S. Malaria control in Indonesia since World War II. Wageningen Agricultural University Papers 1990; 90-7:141-54.
35. Arbani PR. Malaria control program in Indonesia. In: Salazar NP, Chongsuphajaisiddhi TC, Harinasuta T, Karbwang J, eds. Advanced knowledge on malaria in Southeast Asia. Vol. 23, Suppl. 4. 1992:29-38.
36. Baird JK, Sismadi P, Masbar S, et al. A focus of endemic malaria in Central Java. Am J Trop Med Hyg 1996; 54:98-104.
37. Baird JK, Jones TR, Danudirgo EW, et al. Age-dependent acquired immunity against Plasmodium falciparum among people with 2 years exposure to hyperendemic malaria. Am J Trop Med Hyg 1991; 45:65-76.
38. Baird JK, Purnomo, Basri H, et al. Age-specific prevalence of Plasmodium falciparum among six populations with limited histories of exposure to endemic malaria. Am J Trop Med Hyg 1993; 49:707-19.
39. Baird JK. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol Today 1995; 11:105-11.
40. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Am J Trop Med Hyg 1999; 60:533-41.
41. Looareesuwan S, Wilairatana P, Glanarongran R, et al. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg 1999; 93:637-40.
42. Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 1999; 60:831-6.
43. Fairley NH. Researches on paludrine (M.4888) in malaria: an experimental investigation undertaken by the L.H.Q. Medical Research Unit (A.I.F.), Cairns, Australia. Trans R Soc Trop Med Hyg 1946; 40:105-51.
44. Berman JD, Nielsen R, Chulay JD, et al. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg 2001; 95:429-32.